| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fucoidan is found in brown algae. Extracted from the seaweed species Fucus vesiculosus, Cladosiphon okamuranus, Laminaria japonica and Undaria pinnatifida. In oncology research, fucoidan is most consistently described as an immunomodulatory and anti-angiogenic compound with additional pro-apoptotic and anti-metastatic effects in preclinical models. Mechanistically, fucoidan has been reported to suppress NF-κB and PI3K/AKT signaling, reduce VEGF-mediated angiogenesis, inhibit tumor cell adhesion and invasion, and promote apoptosis through caspase activation and mitochondrial pathways. It may also enhance NK cell and macrophage activity, contributing to anti-tumor immune responses. Effects vary substantially depending on molecular weight, sulfation pattern, and source species. Human clinical data remain limited, and many anticancer claims are derived from in vitro and animal studies. Fucoidan — a heterogeneous family of fucose-rich, sulfated polysaccharides obtained primarily from the cell walls of brown algae. It is classified as a marine-derived polysaccharide nutraceutical and experimental biologic rather than a single chemically defined drug. Standard abbreviations include FUC, FD, LMF or LMWF for low-molecular-weight fucoidan, and OF or oligo-fucoidan for depolymerized preparations. Major sources include Fucus vesiculosus, Undaria pinnatifida, Cladosiphon okamuranus, Saccharina japonica, and related brown seaweeds. Molecular weight, branching, sulfate content, monosaccharide composition, contaminants, and extraction method differ substantially among products and strongly affect biological activity. Primary mechanisms (ranked):
Bioavailability / PK relevance: Intact high-molecular-weight fucoidan has limited and variable gastrointestinal absorption. Small quantities of orally administered fucoidan or fucoidan-derived fractions can be detected in human serum and urine, but systemic exposure is low, assay-dependent, and influenced by molecular weight, sulfation, source species, microbiota, and formulation. Low-molecular-weight and oligosaccharide preparations generally have greater absorption and tissue accessibility than native polymers. Local intestinal, microbiome-mediated, endothelial, and immune effects may therefore be more pharmacologically relevant than direct exposure of distant tumors after ordinary oral supplementation. In-vitro vs systemic exposure relevance: Many direct anticancer experiments use approximately 50–1000 µg/mL fucoidan, concentrations that are unlikely to be reproduced as freely circulating intact polysaccharide after conventional oral dosing. Direct tumor-cell apoptosis and kinase inhibition demonstrated at these levels should therefore be considered high-concentration or formulation-dependent findings. Lower-concentration receptor, endothelial, coagulation, intestinal, and immune effects may be more clinically plausible. Nanoparticle, injectable, radiolabelled, and chemically depolymerized fucoidan preparations are not pharmacokinetically interchangeable with oral seaweed extracts. Clinical evidence status: Predominantly preclinical, with several small human studies and randomized adjunct trials. Small colorectal and rectal cancer studies have reported possible improvements in disease control, treatment tolerance, quality of life, or selected inflammatory outcomes, and a 2025 randomized trial reported improved outcomes when low-molecular-weight fucoidan was added to transarterial chemoembolization for unresectable hepatocellular carcinoma. However, studies remain heterogeneous, generally small, formulation-specific, and insufficient to establish fucoidan as an anticancer treatment. Additional randomized phase II studies are registered for cancer-related fatigue, cachexia, chemoradiotherapy, and other supportive indications. Fucoidan is not an approved anticancer drug and no oncology guideline currently recommends routine therapeutic use. Safety and interaction constraints: Oral preparations have generally been well tolerated in small studies, but safety cannot be generalized across poorly standardized extracts. Fucoidan can exhibit anticoagulant, antiplatelet, or fibrinolytic activity depending on molecular weight and sulfation; caution is appropriate with warfarin, heparins, direct oral anticoagulants, antiplatelet drugs, bleeding disorders, or perioperative use. Seaweed-derived products may also contain variable iodine, sodium, heavy metals, or other polysaccharides. Potential interactions with chemotherapy, immunotherapy, and drug absorption remain incompletely characterized. Fucoidan Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: TCGA |
| Type: Antiapoptotic |
| Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response. -One way to estimate Nrf2 induction is through the expression of NQO1. NQO1, the most potent inducer: SFN 0.2 μM, quercetin (2.5 μM), curcumin (2.7 μM), Silymarin (3.6 μM), tamoxifen (5.9 μM), genistein (6.2 μM ), beta-carotene (7.2μM), lutein (17 μM), resveratrol (21 μM), indol-3-carbinol (50 μM), chlorophyll (250 μM), alpha-cryptoxanthin (1.8 mM), and zeaxanthin (2.2 mM) 1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects. 2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death. 3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress -In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies. -Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate. Decreased Nrf2 expression: Skine, Liver, Pancreatic. -Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer - "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1. Nrf2 Inhibitors and Activators Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api - potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue. – In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis. – In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity. – This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming. – Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies. – High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types. – While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression. NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS). -Brusatol: most cited natural inhibitors of Nrf2. -Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent. -Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent . -Oridonin: -Wogonin: although its effects might be cell‑ and dose‑specific. - Withaferin A |
| 7012- | Fuc, | Fucoidan: A promising natural therapeutic agent for protecting human kidney health |
| - | Review, | EC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:81 Target#:226 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid